GMED:NYE-Globus Medical (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 72.35

Change

-0.63 (-0.86)%

Market Cap

USD 9.77B

Volume

0.76M

Analyst Target

USD 60.85
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-1.74 (-1.36%)

USD 220.05B
MDT Medtronic PLC

-1.85 (-2.20%)

USD 106.32B
ZBH Zimmer Biomet Holdings Inc

-4.70 (-4.61%)

USD 22.25B
STE STERIS plc

-2.97 (-1.33%)

USD 22.15B
SNN Smith & Nephew SNATS Inc

-0.02 (-0.08%)

USD 11.31B
PEN Penumbra Inc

+1.99 (+0.74%)

USD 10.50B
BIO Bio-Rad Laboratories Inc

-4.64 (-1.86%)

USD 6.94B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 6.39B
GKOS Glaukos Corp

+1.61 (+1.73%)

USD 5.78B
INSP Inspire Medical Systems Inc

-3.46 (-2.31%)

USD 4.39B

ETFs Containing GMED

EKG First Trust Nasdaq Lux Di.. 4.16 % 0.00 %

-0.04 (-0.53%)

USD 2.29M
CIB0:XETRA VanEck Bionic Engineering.. 3.88 % 0.00 %

+0.07 (+-0.53%)

N/A
CYBG:LSE VanEck Bionic Engineering.. 3.35 % 0.00 %

-0.08 (-0.53%)

N/A
EASI 2.82 % 0.75 %

N/A

N/A
GGEM:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.53% 57% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.53% 57% F 26% F
Trailing 12 Months  
Capital Gain 39.70% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.70% 88% B+ 94% A
Trailing 5 Years  
Capital Gain 63.28% 76% C+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.28% 76% C+ 52% F
Average Annual (5 Year Horizon)  
Capital Gain 11.30% 61% D- 70% C-
Dividend Return 11.30% 61% D- 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.64% 55% F 31% F
Risk Adjusted Return 35.72% 76% C+ 51% F
Market Capitalization 9.77B 80% B- 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.